Improved cancer patient care driven by data

We are contributing to this work by:

Developing

innovative molecular tests, for identifying the characteristics of the tumor.

Collecting and storing

knowledge of and information about the patient and their tumor.

Integrating

the information and knowledge with treatment outcome to accelerate scientific research. This enables us to learn from the data of today’s patients and provide better treatment for the patients of tomorrow.

Vrouw en man spreken in behandelkamer met vrouwelijke arts, zittend aan een overlegtafel

Share your data

Your contribution to improving the treatment of tomorrow’s patients is important. Share your data, too!

Read more

Share your data and share our vision for the future of cancer diagnosis

Read the latest news

Hartwig advances precision oncology worldwide with oncoanalyser

Hartwig advances precision oncology worldwide with oncoanalyser

07-09-2026

Nicole Schonrock on scaling precision care for patients with cancer in Australia Hartwig Medical Foundation has developed powerful software for …

Oncoanalyser 3.0 for cancer genomics is out, now also supporting Ultima Genomics & Roche platforms

Oncoanalyser 3.0 for cancer genomics is out, now also supporting Ultima Genomics & Roche platforms

04-09-2026

Extensive work on the underlying WiGiTS tools now enable users to analyze sequencing data from three sequencing platforms (Illumina, Ultima …

New study using Hartwig Medical Foundation data maps how breast cancer’s genetic makeup shifts when it spreads

New study using Hartwig Medical Foundation data maps how breast cancer’s genetic makeup shifts when it spreads

16-07-2026

Analysis of nearly 1,300 tumor genomes across ten genomic subtypes points to candidate drug targets and biomarkers for metastatic breast …

Hartwig receives CE certification for OncoAct, the first complete IVDR-certified whole-genome cancer diagnostics solution 

Hartwig receives CE certification for OncoAct, the first complete IVDR-certified whole-genome cancer diagnostics solution 

01-07-2026

We are proud to announce that Hartwig Medical Foundation has received CE certification under the European In Vitro Diagnostic Regulation …

Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment

Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment

25-06-2026

Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …

Hartwig and Ultima Expand Collaboration to Advance WGS in Oncology Care 

Hartwig and Ultima Expand Collaboration to Advance WGS in Oncology Care 

12-06-2026

Hartwig and Ultima strengthen collaboration on whole‑genome sequencing  Hartwig Medical Foundation to adopt Ultima Genomics’ UG200 sequencing system to accelerate …

Read all our news

Read the latest blogs

Expansion of the Hartwig Client Portal: registration becomes easier, safer, and smarter

Expansion of the Hartwig Client Portal: registration becomes easier, safer, and smarter

07-08-2026

The expansion of the Hartwig Client Portal marks another important step in further digitizing the collaboration between Hartwig Medical Foundation …

Read more
DataNexus connects clinical and genomic data

DataNexus connects clinical and genomic data

12-05-2026

DataNexus is a project initiated by the Netherlands Cancer Institute–Antoni van Leeuwenhoek (NKIAvL) to improve data availability by integrating clinical …

Read more
How do you analyze 8,000 Tumor/Normal genomes in under two months?

How do you analyze 8,000 Tumor/Normal genomes in under two months?

06-03-2026

It has been a long time coming: Hartwig Medical Foundation has transitioned to the GRCh38 (hg38) reference genome! For years, …

Read more
Read all our blogs

Would you like to be kept up to date with new developments?

Sign up for our newsletters

Want to know more about the complete DNA test?

Visit OncoAct.nl